{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.2","value":"10.8"}]}],"title":"Prior to vaccine administration (Week 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.0","value":"31.0"}]}],"title":"Prior to vaccine booster (Week 4)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.4","value":"17.2"}]}],"title":"After vaccine booster (Week 8)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Tumor necrosis factor (TFNα) cytokine concentration levels measures in peripheral blood. Higher TFNα levels is associated with good prognosis.","dispersionType":"Standard Deviation","groups":[{"description":"α DC1 vaccine\n\nand\n\nChemokine Modulatory Regimen:\n\nCelecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \\& and Fri, only) Interferon Alfa-2b: Intravenous infusion - 5 MU/m\\^2 or 20 MU/m\\^2 (T-Fri)","id":"OG000","title":"α DC1 Vaccine + 1 Cycle of Chemokine Modulatory Regimen"}],"paramType":"MEAN","populationDescription":"Patients treated with at least 1 course of α DC1 vaccine + 1 cycle of chemokine modulatory regimen who were evaluable for completing surgery and response to treatment, and with ≥80% of samples available with measurable cytokine profiles via peripheral blood assay.","reportingStatus":"POSTED","timeFrame":"Prior to vaccine administration (Week 1), prior to vaccine booster (Week 4) and after vaccine booster (Week 8)","title":"Tumor Necrosis Factor (TFNα) Cytokine Levels","type":"SECONDARY","unitOfMeasure":"pg/mL"}